Despite positive EPS growth, Matthews International's share price hasn't followed the trend. The CEO's high remuneration, above industry median, may concern shareholders. The company's decent but not amazing performance, with modest EPS growth and slight revenue increase, contrasts with an 8.0% share decline over three years.
Matthews International's P/S is surprising given its muted revenue growth forecasts versus the industry. Shareholders may face risk as sluggish growth could pressure share prices, potentially leading to investment loss and inflated costs for prospective buyers.
Matthews International's average ROE isn't impressive given the high debt. High debt risks should be evaluated when gauging a company's financial performance via ROE. Debt may enhance returns, while posing financial risks to the company's health.
It's forecasted that Matthews International's profits will improve next year, despite the impact of unusual items from the last year. It seems the company's statutory profit could be understating its potential earnings.
Matthews International's continuous ROCE and capital decline may hint at a mature, possibly shrinking business. With past growth phase, long-term gains are rare. However, investors may anticipate trend reversal, considering the modest stock increase in the last five years.
马修国际股票讨论区
营收近5年来变化不大,基本就在15到16亿之间,只有2021年达到了16.7亿。
营业利润近3年下滑严重,净利润则在2019和2020年亏损两年,2021年勉强扭亏,2022前三季度营收增长5.9%,营业利润下滑15.9%,净利润则再次亏损。
目前市盈率282,市盈率TTM已经亏损,即使以2018年1.07亿净利润计算,市盈率也达到了7.3,没有什么吸引力。
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $辉瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
暂无评论